Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia
Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia
复制标题
DOI：
10.3109/10428194.2010.507829
复制
发表时间：
2010-10-01
影响因子：
2.6
通讯作者：
Koga, Daisuke
中科院分区：
文献类型：
--
作者：
Miyawaki, Shuichi;Hatsumi, Nahoko;Koga, Daisuke
我们回顾性分析了外周血中维尔姆斯肿瘤基因 1 (WT1) mRNA 水平预测 50 名 AML 患者预后的潜力。达到完全缓解 (CR) 后，34 名患者 (69.4%) 被确定为 WT1 阳性，15 名患者 (30.6%) 为阴性。阳性和阴性患者的复发率分别为 73.5% 和 40.0% (p = 0.02)。巩固治疗后，只有 15 名患者 (32.6%) WT1 呈阳性，31 名患者 (67.4%) 呈阴性。尽管阳性和阴性患者的复发率分别为80.0%和54.8% (p = 0.10)，但阳性患者1年内复发率为73.3%，阴性患者仅为33.3% (p = 0.01)。阳性患者的 3 年无病生存率 (DFS) 为 20.0%，阴性患者为 50.0%（p = 0.01）。阳性患者和阴性患者的 3 年总生存率 (OS) 分别为 42.8% 和 69.8% (p = 0.04)。外周血中WT1 mRNA水平可以预测CR后的复发，巩固治疗后其水平与DFS、OS和早期复发密切相关。
We retrospectively analyzed the potential of Wilms' tumor gene 1 (WT1) mRNA levels in peripheral blood for predicting the prognosis of 50 patients with AML. After achieving complete remission (CR), 34 patients (69.4%) were determined to be positive and 15 (30.6%) were negative for WT1. The relapse rate of the positive and negative patients was 73.5% and 40.0% (p = 0.02), respectively. After consolidation therapy, only 15 patients (32.6%) were positive and 31 (67.4%) were negative for WT1. Although the relapse rate of the positive and negative patients was 80.0% and 54.8% (p = 0.10), respectively, the rate of relapse within 1 year was 73.3% in positive patients and only 33.3% in negative patients (p = 0.01), respectively. The disease-free survival (DFS) rate at 3 years was 20.0% for positive patients and 50.0% for negative patients (p = 0.01). The overall survival (OS) rate at 3 years was 42.8% in positive patients and 69.8% in negative patients (p = 0.04), respectively. WT1 mRNA levels in the peripheral blood can predict relapse after CR, and its levels after consolidation therapy are closely correlated with DFS, OS, and early relapse.